MX368017B - Compuestos de indazol como agonistas del receptor de 5-ht4. - Google Patents
Compuestos de indazol como agonistas del receptor de 5-ht4.Info
- Publication number
- MX368017B MX368017B MX2016007857A MX2016007857A MX368017B MX 368017 B MX368017 B MX 368017B MX 2016007857 A MX2016007857 A MX 2016007857A MX 2016007857 A MX2016007857 A MX 2016007857A MX 368017 B MX368017 B MX 368017B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- receptor agonists
- indazole compounds
- formula
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con compuestos de indazol novedosos de la fórmula (I), incluyendo sus estereoisómeros y sus sales farmacéuticamente aceptables. La presente invención también se relaciona con métodos de elaboración de tales compuestos y de composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos de la presente invención son útiles en el tratamiento de varios trastornos que se relacionan con agonistas de receptores de 5-hidroxitriptamina 4 (5-HT4). (Ver fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN5852CH2013 | 2013-12-16 | ||
PCT/IN2014/000116 WO2015092804A1 (en) | 2013-12-16 | 2014-02-24 | Indazole compounds as 5-ht4 receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016007857A MX2016007857A (es) | 2016-09-07 |
MX368017B true MX368017B (es) | 2019-09-13 |
Family
ID=50736125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016007857A MX368017B (es) | 2013-12-16 | 2014-02-24 | Compuestos de indazol como agonistas del receptor de 5-ht4. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9951045B2 (es) |
EP (1) | EP3099675B1 (es) |
JP (1) | JP6161823B2 (es) |
KR (1) | KR101824154B1 (es) |
CN (1) | CN105873920B (es) |
AP (1) | AP2016009253A0 (es) |
AU (1) | AU2014369085B2 (es) |
BR (1) | BR112016013974B1 (es) |
CA (1) | CA2932428C (es) |
DK (1) | DK3099675T3 (es) |
EA (1) | EA029951B1 (es) |
ES (1) | ES2668873T3 (es) |
IL (1) | IL245948B (es) |
MX (1) | MX368017B (es) |
NZ (1) | NZ720879A (es) |
SG (1) | SG11201604849YA (es) |
WO (1) | WO2015092804A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS60804B1 (sr) | 2014-08-16 | 2020-10-30 | Suven Life Sciences Ltd | Proces proizvodnje 1-izopropil-3-{5-[1-(3-metoksipropil)piperidin-4-il]-[1,3,4]oksadiazol-2-il}-1h-indazol oksalata u velikom obimu |
PT3265459T (pt) * | 2015-02-13 | 2019-07-17 | Suven Life Sciences Ltd | Compostos amidos como agonistas do recetor 5-ht4 |
JP6900028B2 (ja) * | 2017-03-29 | 2021-07-07 | 国立大学法人帯広畜産大学 | パーキンソン病に併発した認知障害の治療剤 |
EP3628660A1 (en) * | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases |
EP4317141A1 (en) | 2022-08-04 | 2024-02-07 | Curia Spain S.A.U. | Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5150393A (en) | 1992-10-13 | 1994-05-09 | Smithkline Beecham Plc | Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists |
NZ257545A (en) | 1992-11-05 | 1997-01-29 | Smithkline Beecham Plc | Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions |
ES2248616T3 (es) | 2001-10-22 | 2006-03-16 | Pfizer Inc. | Compuestos imidazopiridina como moduladores del receptor 5-ht4. |
BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
EP1689742B1 (en) | 2003-11-24 | 2010-03-17 | Pfizer, Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
CA2551171C (en) * | 2003-12-23 | 2012-07-10 | Bio-Medisinsk Innovasjon As | Modulators of peripheral 5-ht receptors |
RU2404179C2 (ru) * | 2004-12-22 | 2010-11-20 | Тереванс, Инк. | Индазол-карбоксамидные соединения |
US8816090B2 (en) | 2005-02-25 | 2014-08-26 | Pfizer Inc. | Benzisoxazole derivatives |
US7906532B2 (en) | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
ES2640752T3 (es) | 2010-02-12 | 2017-11-06 | Askat Inc. | Agonistas del receptor 5-HT4 para el tratamiento de la demencia |
EP2536713A1 (en) | 2010-02-16 | 2012-12-26 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
KR101551481B1 (ko) * | 2011-09-19 | 2015-09-08 | 수벤 라이프 사이언시스 리미티드 | 5-ηt4 수용체 리간드인 헤테로아릴 화합물 |
-
2014
- 2014-02-24 AU AU2014369085A patent/AU2014369085B2/en not_active Ceased
- 2014-02-24 ES ES14725246.4T patent/ES2668873T3/es active Active
- 2014-02-24 NZ NZ720879A patent/NZ720879A/en not_active IP Right Cessation
- 2014-02-24 AP AP2016009253A patent/AP2016009253A0/en unknown
- 2014-02-24 CN CN201480068132.6A patent/CN105873920B/zh active Active
- 2014-02-24 SG SG11201604849YA patent/SG11201604849YA/en unknown
- 2014-02-24 EA EA201691252A patent/EA029951B1/ru unknown
- 2014-02-24 BR BR112016013974-7A patent/BR112016013974B1/pt active IP Right Grant
- 2014-02-24 EP EP14725246.4A patent/EP3099675B1/en active Active
- 2014-02-24 KR KR1020167015974A patent/KR101824154B1/ko active IP Right Grant
- 2014-02-24 JP JP2016539987A patent/JP6161823B2/ja active Active
- 2014-02-24 WO PCT/IN2014/000116 patent/WO2015092804A1/en active Application Filing
- 2014-02-24 US US15/104,521 patent/US9951045B2/en active Active
- 2014-02-24 CA CA2932428A patent/CA2932428C/en active Active
- 2014-02-24 DK DK14725246.4T patent/DK3099675T3/en active
- 2014-02-24 MX MX2016007857A patent/MX368017B/es active IP Right Grant
-
2016
- 2016-05-31 IL IL245948A patent/IL245948B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MX2016007857A (es) | 2016-09-07 |
JP2016540796A (ja) | 2016-12-28 |
BR112016013974A8 (pt) | 2018-01-30 |
US9951045B2 (en) | 2018-04-24 |
CA2932428C (en) | 2017-10-24 |
KR101824154B1 (ko) | 2018-03-14 |
DK3099675T3 (en) | 2018-05-22 |
KR20160075832A (ko) | 2016-06-29 |
EP3099675A1 (en) | 2016-12-07 |
JP6161823B2 (ja) | 2017-07-12 |
IL245948B (en) | 2019-08-29 |
WO2015092804A1 (en) | 2015-06-25 |
BR112016013974B1 (pt) | 2022-11-22 |
AU2014369085B2 (en) | 2017-02-23 |
ES2668873T3 (es) | 2018-05-22 |
CN105873920B (zh) | 2018-06-08 |
EP3099675B1 (en) | 2018-02-14 |
NZ720879A (en) | 2017-05-26 |
SG11201604849YA (en) | 2016-07-28 |
IL245948A0 (en) | 2016-08-02 |
EA201691252A1 (ru) | 2016-12-30 |
AP2016009253A0 (en) | 2016-06-30 |
EA029951B1 (ru) | 2018-06-29 |
US20160311797A1 (en) | 2016-10-27 |
CN105873920A (zh) | 2016-08-17 |
BR112016013974A2 (pt) | 2017-08-08 |
CA2932428A1 (en) | 2015-06-25 |
AU2014369085A1 (en) | 2016-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
EA201490357A1 (ru) | Индазолы | |
TN2015000034A1 (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
EA201700042A1 (ru) | Соединения имидазопиридазина | |
PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
TN2016000511A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
MX364929B (es) | Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |